Mianserin Viatris (Mianserin Hydrochloride)

Mianserin blocks central α2‑adrenergic receptors, which increases the release of norepinephrine. It also antagonises several serotonin receptors (5‑HT2 and 5‑HT3) and histamine H1 receptors, leading to enhanced noradrenergic and serotonergic neurotransmission that contributes to its antidepressant effect.

The dosage of Mianserin Viatris is determined individually by a qualified prescriber based on the patient’s clinical condition, response to therapy, and tolerability. Patients should follow the prescribing information provided by their healthcare professional and not adjust the dose without medical advice.

Safety data for Mianserin in pregnancy and lactation are limited. The prescriber should weigh the potential benefits against possible risks to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternative treatment options with their healthcare provider.

To request Mianserin Viatris, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mianserin belongs to the tetracyclic antidepressant class, differing from selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs) in its receptor profile. It has stronger antihistaminic and anticholinergic activity, which can lead to more sedation and weight gain but may be advantageous for patients needing these effects.

Mianserin Viatris should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain its stability and potency throughout its shelf life.

Mianserin Viatris is taken orally, usually with or without food, as directed by the prescribing clinician. The tablets should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious risks include agranulocytosis, seizures, severe hypotension, cardiac arrhythmias, and the emergence or worsening of suicidal thoughts. Patients should be monitored closely for signs of these conditions, and any concerning symptoms should prompt immediate medical evaluation.

Mianserin is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs) or those with known hypersensitivity to the drug. Caution is also advised for individuals with uncontrolled hypertension, severe liver disease, or a history of seizures. The prescriber will assess suitability before initiating therapy.